LENA Q51® is the first Leukemia diagnostic test able to test up to 51 genes mutations.
The innovative approach of LENA Q51® Leukemia Fusion Gene Kit is to target gene mutations, clonogenic gene rearrangements and abnormal gene expression. Fusion genes are one of the most common biomarkers in Leukemia and are caused by chromosome breakage and recombination. Test results are available in under three hours using a standard qPCR machine compared with traditional microbiology methods, which can take two to three days and longer to provide results.
The test has an easy-to-use protocol and can be run on standard qPCR equipment and is designed to handle the workflow in a clinical microbiology lab environment. The RUO LENA Q51®employs industry standard PCR and DNA purification technology.
Using Lena Q51 avoid using a series of tests. We highly recommend Lena Q51 instead of all the series of additional tests that we offer as well as an alternative. One test is more comfortable for the patient.
BCR-ABL1 refers to a gene sequence found in an abnormal chromosome 22 of some people with certain forms of leukemia.
Unlike most cancers, the cause of chronic myelogenous leukemia (CML) and some other leukemias can be traced to a single, specific genetic abnormality in one chromosome.
The presence of the gene sequence known as BCR-ABL1 confirms the diagnosis of CML and a form of acute lymphoblastic lymphoma (ALL), specifically a type of B-lymphoblastic leukemia/lymphoma. In very rare cases, the abnormal chromosome is linked to cases of acute myeloid leukemia and T-lymphoblastic leukemia/lymphoma.